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INTRODUCTION
Haemophilus influenzae type b (Hib) was the leading cause
of bacterial meningitis and a major cause of other serious
invasive diseases among children aged <5 yr before Hib con-
jugate vaccines became available in 1988 (1). After routine
use of Hib conjugate vaccines, dramatic reductions in the
incidence of invasive diseases have been noted (2). For exam-
ple, in the U.S. all infants were recommended to receive Hib
conjugate vaccines starting at age 2 months; by 1996, the
incidence of Hib invasive disease among children aged <5
yr declined by >99% (3). 
However, the efficacy and effectiveness of a vaccine depends on
a variety of factors, including the local disease burden, genet-
ic susceptibility, age, type of vaccine, vaccination schedule,
etc. In order to introduce the Hib vaccine into a country,
these factors must be considered with discretion. An impor-
tant factor is the extent of the local Hib disease burden. Before
the introduction of Hib conjugate vaccine, the incidence of
invasive Hib disease in the Apache Indians and Alaskan natives
was very high as 250 and 400 to 600 cases per 100,000 chil-
dren under 5 yr of age, respectively (4, 5). In Spain and Swe-
den, the incidence was 12 to 54 cases per 100,000 children
under age 5 yr, respectively. Hib meningitis incidence rates
in Asia were reported <20 per 100,000 children younger
than 5 yr of age (2). Another important factor is the type of
vaccine. There are four different conjugate vaccines commer-
cially available against Hib disease; with a continuous release
in various combinations with other vaccines. Differences are
determined by the conjugate protein and the method to con-
jugate the polyribosylribitol phosphate (PRP). The first con-
jugate produced was the diphtheria toxoid conjugate (PRP-
D), followed by mutant diphtheria toxin conjugate (PRP-
CRM), meningococcal outer membrane protein conjugate
(PRP-OMP) and tetanus toxoid conjugate (PRP-T). All four
Hib conjugate vaccines have been shown to be highly effi-
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Immunogenicity and Safety of Two Different Haemophilus influenzae
Type b Conjugate Vaccines in Korean Infants
The incidence of invasive diseases, including meningitis caused by Haemophilus
influenzae type b (Hib) was markedly decreased after routine immunization of Hib
vaccine through diverse schedules in many countries. The purpose of this study
was to evaluate the immunogenicity and safety of Hib conjugate vaccines in Kore-
an children before the implementation of a national immunization program against
Hib in Korea. A multicenter controlled trial was performed on two different Hib vac-
cines in Korean children. A total of 319 infants were enrolled: 199 infants were
immunized with the Hib polysaccharide conjugated to the tetanus toxoid (PRP-T)
and 120 infants with the Hib polysaccharide conjugated to the outer-membrane
protein of Neisseria meningitides (PRP-OMP). Immunogenicity was evaluated by
enzyme-linked immunosorbent assay (ELISA) and serum bactericidal assay. Both
vaccines showed good immunologic responses after primary immunization. After
2 doses of PRP-T or PRP-OMP, 78.9% and 91.7% of infants achieved an anti-
body level of ≥1.0 μ g/mL, respectively. Both vaccines were safe and well-tolerat-
ed. No serious adverse events were observed. Thus, Hib conjugate vaccines appear
to be safe and show good immunogenicity in Korean infants. These results will be
important reference data for the implementation of Hib vaccine in the national immu-
nization program of Korea. 
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als; however, there are differences in the immune response
to each of the vaccines. In infants, PRP-T and PRP-CRM
elicit high levels of anti-PRP antibody after 3-dose primary
series, whereas PRP-OMP produces a significant immune
response after one injection (6). Therefore, PRP-OMP was
chosen for populations that had a higher proportion of dis-
ease in the first 6 months of life. Difference in vaccine response
between populations is another important factor. Even with
the same Hib conjugate vaccine (PRP-D), differences in vac-
cine performance were observed in Alaska and Finland. The
efficacy in Finnish infants under 2 yr of age was 94% where-
as there was no demonstrable efficacy in the Alaskan popu-
lation (7). The influence of ethnic difference on immuno-
logic responses has also been demonstrated in other studies
(8, 9). 
Hib conjugate vaccines were very safe and highly effective
in a wide variety of epidemiologic settings in more than 13
yr worldwide experience (2). By the end of 2005, Hib vac-
cines were part of the routine infant immunization program
in 101 countries (10). To introduce the Hib conjugate vac-
cine into the national immunization program in Korea, a
nationwide study on the epidemiologic status in relation to
the disease burden of invasive Hib diseases as well as cost-
effectiveness study is urgent. Moreover, the appropriate sched-
ule should be determined. 
The objective of this study was to evaluate the immuno-
genicity and safety of two Hib conjugate vaccines (PRP-T
and PRP-OMP) as a primary series in Korean infants and
especially evaluate the immunogenicity after 2 doses of the
Hib conjugate vaccine to examine the possibility of adopt-
ing 2 doses as a primary series.
MATERIALS AND METHODS
Study design and subjects
A total of nine centers throughout the Republic of Korea
were involved in the multicenter clinical study designed to
evaluate the immunogenicity and safety of two Hib vaccines
for primary immunization of infants. The study protocol was
approved by the Institutional Review Board at each center
and was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines. After writ-
ten informed consent forms were obtained from parents or
guardians, healthy infants aged 6-12 weeks (43-91 days) and
born after the gestational period of 37 weeks were enrolled in
the study. Subjects were excluded if they had a history of
Hib disease, immunosuppressive disorder, immunoglobulin
therapy, blood transfusion, neurologic disease or acute or
chronic disease at the time of enrollment. Enrollment began
in March 2005 and ended in November 2005. 
Vaccines
Two conjugate vaccines were tested; PRP-T (ActHIB
�,
Aventis Pasteur S.A., Lyon, France) and PRP-OMP (Liquid-
PedHIB
�, Merck & Co., Inc, Whitehouse Station, NJ, U.S.A.).
Infants were immunized with the PRP-T vaccine at 2, 4,
and 6 months of age or with the PRP-OMP vaccine at 2
and 4 months of age. Infants received a 0.5 mL injection
intramuscularly on the anterolateral side of the thigh. Some
children were administered other vaccines (i.e., diphtheria-
tetanus-acellular pertussis, inactivated poliovirus, hepatitis
B, influenza or others) simultaneously on the contralateral
leg. All vaccines were stored at 2 to 8℃until vaccination. 
Sera
Because one of the objectives of this study was to compare
the differences of 2 doses and 3 doses for a primary vaccine
schedule, infants vaccinated with the PRP-T vaccine were
divided into two groups. The 1st group had serum samples
collected before vaccination (Pre), at the time of the second
dose (Post I) and 1 month after the third dose (Post III). The
2nd group had serum samples collected before vaccination
(Pre), at the time of the third dose (Post II) and 1 month
after the third dose (Post III). Infants vaccinated with the
PRP-OMP vaccine had samples collected before vaccination
(Pre), at the time of the second dose (Post I) and 1 month
after the second dose (Post II). Sera were stored at -20℃until
analysis.
Immunogenicity
Anti-PRP antibodies were measured by an enzyme-linked
immunosorbent assay (ELISA) modification previously des-
cribed (11, 12). The ELISA was done at the Center for Vac-
cine Evaluation and Study, Ewha Medical Research Insti-
tute at Ewha Womans University. HbO-HA (Hib oligosac-
charide conjugated to human serum albumin, provided by
Moon Nahm, University of Alabama at Birmingham, Birm-
ingham, AL, U.S.A.) was used as the antigen and the stan-
dard curve was generated by using reference serum lot 1983
(provided by Carl Frasch, Center for Biological Evaluation
and Review, Food and Drug Administration, Bethesda, MD,
U.S.A.) with a calculated IgG antibody concentration of 60.9
μ g/mL. The cut-off of the ELISA for PRP was 0.15 μ g/mL.
Seroprotection was defined as the antibody concentration
≥1.0 μ g/mL after vaccination. Seroprotection response rate
was analyzed. Proportions of subjects achieving levels ≥0.15
μ g/mL were also calculated.
A serum bactericidal assay (SBA) was done to evaluate
functional antibodies that can efficiently bind to the PRP
capsule of Hib and fix complement onto the bacterial sur-
face to initiate phagocytosis. A standardized SBA assay, which
measures the direct bactericidal activity of serum antibodies
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tocol. This protocol was previously described by Romero-
Steiner et al. (13) and modified by Schlesinger et al. (14). The
SBA was done with sera obtained after the 2nd dose of PRP-
T and 1 month after the last vaccination in both groups.
Two-fold serial dilutions of sera were made with dilution
buffer made from Hanks buffer (Gibco Laboratories, Grand
Island, NY, U.S.A.) with Ca++ and Mg++ and 2% Fildes
enrichment (BBL Becton Dickinson and Company, Sparks,
MD, U.S.A.). Ten μ L of diluted serum was added in dupli-
cate to wells of a microtiter plate. A frozen aliquot of Hib
Eagan strain was diluted to yield 1,000 bacteria in a 20 μ L
volume of dilution buffer and added to each well. After incu-
bation for 15 min at 37℃ in a 5% CO2 incubator, 25 μ L of
baby rabbit complement (Pel-Freez, Brown Deer, WI, U.S.A.)
and 25 μ L of dilution buffer were added to each well. After
the plates were incubated for 60 min at 37℃ in a 5% CO2
incubator, 5 μ L of the reaction mixture was plated on a choco-
late II agar plate and was incubated for 15 hr at 37℃ in a
5% CO2 incubator. 
The bactericidal titer of a serum sample was defined as the
dilution of the serum sample that resulted in half as many
colonies as were seen with controls. If an undiluted serum
sample killed 50% of colonies, then the bactericidal titer
was 4 in our system. A control serum sample (in house QC
sera which has an assigned value of anti-PRP antibody con-
centration) was included in each assay to monitor assay repro-
ducibility.
Safety 
After each vaccination, infants were observed for approxi-
mately 30 min. Parents or guardians received a diary card to
record the occurrence and intensity of specific solicited local
reactions (tenderness, redness, and swelling) and systemic
reactions (fever, irritability, drowsiness, and loss of appetite)
on the day of vaccination and for three subsequent days. Injec-
tion site redness or swelling was recorded in the exact diam-
eter. Redness and swelling measured ≥5 mm in diameter
were considered clinically relevant. Fever was defined as axil-
lary body temperature ≥37.5℃. The intensity of symp-
toms was graded on a scale of 0-3. Grade 3 symptoms were
defined as follows: for local tenderness, spontaneously painful
limb; for local redness and swelling, diameter ≥30 mm;
for fever, axillary temperature ≥39.0℃; for irritability, cry-
ing that could not be comforted or preventing normal activi-
ty; for drowsiness, drowsiness that prevents normal activity;
for loss of appetite, not eating at all; and for any other adverse
event, preventing normal activity. 
Other serious adverse events were also monitored. Adverse
events were defined as a visit to a medical doctor or emer-
gency room or any medication required for any reason. Par-
ents or guardians were asked to record severe adverse events
occurring within 30 days following each vaccine adminis-
tration and to contact the investigator immediately if the
infant manifested any serious signs or symptoms that need
immediate medical attention. 
Statistical analysis
Primary immunogenicity analyses were based on the accord-
ing-to-protocol cohort, which included all subjects who met
the eligibility criteria and those who complied with the pro-
cedures of the protocol. All safety analyses were descriptive
and based on the modified intent-to-treat cohort, which
included all vaccinated infants for whom safety data were
available.
Serologic calculations were performed on logarithmically
transformed data. Antibody responses were assessed by cal-
culating the geometric mean titers (GMT) with their 95%
confidence intervals (CI) and seroprotection response rates.
Antibody concentrations below the cut-off value of 0.15 μ g/
mL were arbitrarily assigned a value corresponding to half
the cut-off value of the test as 0.08 μ g/mL. The results were
compared with the Students t-test and chi-square test (p<
0.05). A correlation between anti-PRP antibody titers by
the ELISA and bacteridical titer by SBA were evaluated. If
bacteria were not killed with an undiluted serum sample,
then the bactericidal titer were arbitrarily assigned a value
corresponding to half the cut-off value of the test as 2. 
The analysis of safety was performed based on the percent-
age of the incidence of each local and systemic reaction over
all doses. The results were compared with the chi-square
test (p<0.05).
RESULTS
Subjects
A total of 319 Korean infants were enrolled in the prima-
ry vaccination study: 199 in the PRP-T group and 120 in
the PRP-OMP group. Approximately half of the subjects
(53.9%) were male. One hundred forty nine (74.9%) infants
in the PRP-T group and 72 (60.0%) infants in the PRP-
OMP group completed the study. Sixteen injections with
the PRP-T and 34 injections with the PRP-OMP were elim-
inated from the safety analysis due to missing of essential
data or safety documentation. None of these eliminated sub-
jects reported a serious adverse event. Fifty cases (25.1%) in
the PRP-T group and 48 cases (40.0%) in the PRP-OMP
group were withdrawn during the study for the following
reasons: move out of the district (n=2), lost to follow-up
(n=40), parent request (n=27), violation of protocol (n=7),
medication during the study that may have an effect on the
immunogenicity analysis (n=3), and others (n=19).
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Results of the immunogenicity analysis are shown in Table
1 and 2. In both groups the GMT increased significantly
after each dose. In the comparison between the two groups,
the prevaccination GMT was similar in each group. Few
subjects actually had measurable antibody levels. Two months
after the first dose, at the age of 4 months, the GMT was
higher in the PRP-OMP group but not with a significant
difference. After the 2nd dose, the GMT differed significant-
ly in the 2 groups. The GMT in the PRP-OMP group was
significantly higher than the PRP-T group (7.78 vs. 4.46 μ g/
mL, p<0.05). However, the GMT of anti-PRP antibodies 1
month after completion of the primary vaccination course
was significantly higher in the PRP-T vaccines than in the
recipients of PRP-OMP (15.01 vs. 7.78 μ g/mL, p<0.05).
The seroprotection response rate increased significantly
with each dose in both PRP-T and PRP-OMP groups. The
proportion of infants achieving anti-PRP antibody concen-
trations ≥1.0 μ g/mL after the second dose was significantly
higher in infants primed with PRP-OMP than those primed
with PRP-T (p<0.05) and 1 month after completion of the
primary vaccination course, it was significantly higher in the
PRP-T group compared with the PRP-OMP group (97.3
vs. 91.7%, p<0.05). However, in both vaccine groups, the
proportion of infants with anti-PRP antibody concentrations
≥1.0 μ g/mL was higher than 70% after the second dose.
Serum bactericidal activity specific for Hib was done ran-
domly on 62 sera. Twenty sera were collected after 2 doses
of PRP-T, 21 collected after 3 doses, and 21 collected after
2 doses of PRP-OMP. Samples were obtained randomly from
subjects with low to high titers of anti-PRP antibodies. 
In Fig. 1, comparison of anti-PRP IgG titer with SBA
titers in sera after 2 doses of PRP-T vaccine (n=20 serum
samples) (A), in sera after 3 doses of PRP-T vaccine (n=21
serum samples) (B) and in sera after 2 doses of PRP-OMP
vaccine (n=21 serum samples) (C) are shown. The dotted
line represents the detection limit of anti-PRP IgG antibody
titer, 0.15 μ g/mL or serum bactericidal titer, 2. After 2 and
3 doses of PRP-T vaccine, there was one sample with an anti-
body titer ≥0.15 μ g/mL but undetectable bactericidal activi-
ty, respectively. After 2 doses of PRP-OMP vaccine, there
were three samples with an antibody titer ≥0.15 μ g/mL
but undetectable bactericidal activity. All the other samples
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*, Those who were immunized with a PRP-OMP; 
� , compared PRP-T with PRP-OMP after 2 doses, p<0.05; 
� , compared PRP-T with PRP-OMP 1 month
after primary series, p<0.05.
PRP-T, polyribosylribitol phosphate-tetanus toxoid conjugate; PRP-OMP, polyribosylribitol phosphate-meningococcal outer membrane protein conju-
gate; N, number of subjects in the according-to-protocol cohort for immunogenicity with available results; GMT, geometric mean titer; 95% CI, 95%
confidence interval; mo, month.
PRP-T
N
GMT
(μ g/mL)
95% CI
(μ g/mL)
Titer range
(μ g/mL)
PRP-OMP
N
GMT
(μ g/mL)
95% CI
(μ g/mL)
Titer range
(μ g/mL)
2 mo (Pre) 149 <0.15 72 <0.15
4 mo (Post I) 59 0.91 0.65-1.27 0.08-12.53 72 0.98 0.71-1.36 0.08-28.77
6 or 5*mo (Post II) 90 4.46
� 3.06-6.49 0.08-204.14 72 7.78
� ,� 5.54-10.91 0.08-373.57
7 mo (Post III) 149 15.01
� 12.30-18.31 0.58-395.78
Table 1. Geometric mean antibody concentrations after primary vaccination
*, Those who were immunized with a PRP-OMP; 
� , compared PRP-T with PRP-OMP after 2 doses, p<0.05; 
� , compared PRP-T with PRP-OMP 1 month
after primary series, p<0.05.
PRP-T, polyribosylribitol phosphate-tetanus toxoid conjugate; PRP-OMP, polyribosylribitol phosphate-meningococcal outer membrane protein conju-
gate; N, number of subjects in the according-to-protocol cohort for immunogenicity with available results; 95% CI, 95% confidence interval; mo, month.
PRP-T
N % 95% CI
PRP-OMP
N % 95% CI
4 mo (Post I)
≥0.15 μ g/mL 59 89.8 81.8-97.8 72 88.9 81.6-96.1
≥1.0 μ g/mL 59 42.4 29.6-55.2 72 52.8 41.2-64.3
6 or 5*mo (Post II)
≥0.15 μ g/mL 90 93.3 88.1-98.6 72 98.6 95.9-100.0
≥1.0 μ g/mL 90 78.9
� 70.5-87.3 72 91.7
� ,� 85.2-98.1
7 mo (Post III)
≥0.15 μ g/mL 149 100.0 97.4-100.0
≥1.0 μ g/mL 149 97.3
� 94.7-99.9
Table 2. Seroprotection rates after primary vaccination showed bactericidal activity. The PRP-T and PRP-OMP
vaccines in both groups showed comparable correlation be-
tween the ELISA and SBA titers. 
Safety
The safety evaluation was conducted on all enrolled infants.
Both vaccines were safe and well tolerated (Table 3). No seri-
ous adverse reactions were reported. The incidence of grade
3 solicited symptoms was low in both groups. The incidence
of solicited local reactions such as redness and swelling were
higher in the infants immunized with PRP-OMP compared
with the PRP-T. However, there was no significant differ-
ence in other local or systemic reactions between the two
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Grade 3 tenderness, spontaneously painful; grade 3 fever, axillary temperature ≥39°C; grade 3 irritability, crying that could not be comforted/pre-
venting normal activity; grade 3 drowsiness, drowsiness that prevents normal activity; grade 3 poor feeding, not eating at all. 
PRP-T, polyribosylribitol phosphate-tetanus toxoid conjugate; PRP-OMP, polyribosylribitol phosphate-meningococcal outer membrane protein conju-
gate; 95% CI, 95% confidence interval.
PRP-T
Adverse reactions 1st (n=175)
% 95% CI
PRP-OMP
2nd (n=180)
% 95% CI
3rd (n=163)
% 95% CI
1st (n=108)
% 95% CI
2nd (n=90)
% 95% CI
Local reactions
Tenderness
Any 26.9 20.2-33.5 22.8 16.7-28.9 19.0 12.9-25.1 36.1 27.1-45.1 33.3 23.5-43.1
Grade 3 6.3 2.7-9.9 2.2 0.1-4.4 0.6 0.0-1.8 2.8 0.0-5.9 2.2 0.0-5.3
Redness
Any 11.4 6.7-16.1 6.1 2.6-9.6 6.1 2.5-9.8 24.1 16.0-32.1 30.0 20.2-39.8
Grade 3 (≥30 mm) 2.3 0.1-4.5 1.1 0.0-2.7 0.6 0.0-1.8 2.8 0.0-5.9 3.3 0.0-7.1
Swelling
Any 5.7 2.3-9.1 3.9 1.1-6.7 3.7 0.8-6.6 20.4 12.7-28.0 14.4 7.2-21.7
Grade 3 (≥30 mm) 2.9 0.4-5.4 1.1 0.0-2.7 1.2 0.0-2.9 5.6 1.2-9.9 2.2 0.0-5.3
Systemic reactions
Fever
Any 12.0 7.3-16.7 5.0 1.8-8.2 4.3 1.2-7.4 15.7 8.9-22.6 8.9 3.0-14.8
Grade 3 0.0 0.0-1.5 0.6 0.0-1.7 0.6 0.0-1.8 0.9 0.0-2.8 1.1 0.0-3.3
Irritability
Any 56.6 49.2-63.9 36.1 29.1-43.1 31.3 24.2-38.3 65.7 56.7-74.8 47.8 38.0-57.6
Grade 3 8.0 3.9-12.1 5.6 2.2-8.9 1.8 0.0-3.9 5.6 1.2-9.9 4.4 0.1-8.8
Drowsiness
Any 37.1 29.9-44.3 28.3 21.8-34.9 20.9 14.6-27.1 44.4 35.0-53.9 33.3 23.5-43.1
Grade 3 1.7 0.0-3.7 1.7 0.0-3.6 0.6 0.0-1.8 2.8 0.0-5.9 1.1 0.0-3.3
Poor feeding
Any 25.7 19.3-32.2 20.6 14.7-26.5 12.3 7.2-17.4 35.2 26.2-44.2 23.3 14.5-32.2
Grade 3 1.7 0.0-3.7 1.7 0.0-3.6 0.0 0.0-1.6 0.9 0.0-2.8 0.0 0.0-3.1
Table 3. Incidence of adverse reactions reported during the 4-day follow-up period following vaccination
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Fig. 1. Comparison of anti-PRP IgG titer with SBA titers in sera after 2 doses of PRP-T vaccine (n=20 serum samples) (A), sera after 3 doses
of PRP-T vaccine (n=21 serum samples) (B) and sera after 2 doses of PRP-OMP vaccine (n=21 serum samples) (C). The vertical and hori-
zontal dotted lines represent the detection limit of anti-PRP IgG antibody assay (0.15 μ g/mL) and serum bactericidal assay (2), respectively. 
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Anti-PRP lgG (μ g/mL) Cvaccines. The most frequent solicited local reaction was injec-
tion-site tenderness and redness, irritability was the most
common systemic symptom. The incidence of fever of grade
3 intensity (axillary temperature ≥39.0℃) was 0.0-1.1%
with both vaccines for all doses. No substantial increase in
the incidence of symptoms was observed for subsequent doses
in either group. In contrast, the incidence of any reports of
fever, irritability, drowsiness, and poor feeding, tended to
decrease with successive doses.
DISCUSSION
This study aimed to evaluate the immunogenicity and
safety of two Hib conjugate vaccines, PRP-T and PRP-OMP,
in Korean infants. We found that both PRP-OMP and PRP-
T vaccines elicited significant antibody responses after a pri-
mary series of 2 or 3 doses, respectively, and were safe and
well-tolerated without serious adverse reactions.
Studies on Hib conjugate vaccines for infants in Korea
showed a good response to the vaccine (15-19). However,
these previous studies were done on limited numbers of infants
in limited districts. Also, most studies were done on PRP-T
and there are no studies on PRP-OMP. In this study, we com-
pared the immunogenicity and safety of two Hib conjugate
vaccines, PRP-T and PRP-OMP, in a multicenter controlled
clinical trial of 9 centers throughout Korea. The results of
PRP-T vaccine are comparable to the studies done earlier in
Korea (16-19). But there are no comparable data with this
study on the immunogenicity of PRP-OMP in Korea.
The results of this study show that Korean infants had
higher GMTs compared to published data from the U.S. or
European infants (6, 20, 21). Correlates of protection from
invasive Hib diseases are derived from studies of natural
immunity, plain-polysaccharide vaccine responses and passive
immunization (22). The concentration of anti-PRP antibody
≥0.15 μ g/mL is commonly considered predictive of immu-
nity and ≥1 μ g/mL is considered predictive of longer-term
protection from invasive disease (23). After a primary series of
PRP-T at 2, 4, and 6 months of age and PRP-OMP vaccine
at 2 and 4 months of age, infants with an anti-PRP antibody
titer ≥0.15 μ g/mL were 100% and 98.6%, respectively,
and infants with titer ≥1.0 μ g/mL were 97.3% and 91.7%,
respectively. 
Another important finding of this study is that PRP-T
vaccines have resulted in comparable immunogenicity after
the first 2 doses of primary series. According to the World
Health Organization (WHO) recommendations, effective
Hib vaccines have been found to induce ≥1.0 μ g/mL anti-
PRP antibody in 70% or more of the infants 1 month after
the completion of the primary immunization series (24). On
applying this criterion to our study, the results were accept-
able after 2 doses of PRP-T as well as PRP-OMP vaccines. 
Population-based surveillance studies for invasive bacteri-
al disease in Korea show that Hib meningitis incidence rates
may be lower than those in other regions. Considering the
cost-benefit effectiveness with highly priced conjugate vac-
cines, Hib conjugate vaccines have not yet been included in
the routine immunization schedule in Korea. However, regard-
ing the worldwide data of the effectiveness and safety of Hib
vaccines (2) and the serious clinical consequences of the inva-
sive Hib diseases (1), it would be advisable to consider adopt-
ing Hib vaccine in the routine immunization schedule. 
There are ways to overcome the high cost of conjugate
vaccines. The number of doses could be lowered. Instead of
four total doses, several European countries use only two doses
for the primary series with a booster in the second year of
life (25), and they have reported good results (26). Another
alternative is to use smaller antigen doses. In a study of frac-
tional dose regimens, 91% to 100% of Chilean infants immu-
nized with one-half or one-third of a full dose of Hib conju-
gate developed an immune response which was comparable
to those immunized with the full dose (27). Given that the
PRP-T vaccine shows an acceptable rate of immunogenicity
even after 2 doses and PRP-OMP shows good immunogenici-
ty with recommended 2 doses of primary series, a modifica-
tion of the existing regimen of PRP-T or use of PRP-OMP
could be a possibility in the routine immunization schedule
in Korea, where Hib vaccine is often limited and not includ-
ed in the national immunization program because of the high
cost of the vaccine.
The present study evaluates the serum bactericidal activi-
ties, a measure of functional antibody activity. There was a
good correlation between anti-PRP antibody titers with the
serum bactericidal titers in both vaccines. Thus, while the
antibodies elicited reached levels considered protective for
invasive Hib disease, they also elicited functional antibody
activities. Functional antibodies were elicited after 2 doses
of the PRP-OMP and PRP-T conjugate vaccines, also. 
The incidence of local and systemic symptoms occurring
after the primary series of immunization was similar in both
vaccines. Local reactions such as tenderness and swelling were
mild and transient. No increase in local reactions with sub-
sequent injections was observed. The most common systemic
reaction noted was irritability. No serious adverse events rel-
evant to the vaccine were reported throughout the entire
clinical trial.
There have not been many studies on the epidemiology of
invasive Hib diseases in Korea. A population-based study
was done prospectively on bacterial meningitis in Jeonbuk
province from 1999 to 2001 (28). However, the Hib conju-
gate vaccine was already introduced into Korea on a private
sector basis before the start of surveillance and the immuniza-
tion rate was 15.7% for children <5 yr of age. According to
the study, the Hib meningitis incidence was 6.0 (2.9-12.4)
cases per 100,000 children younger than 5 yr old. This is
lower than the incidence reported in the U.S. and other coun-
tries (4, 5); however, this might be due to the limitation in
934 K.H. Kim, H. Lee, E.H. Chung, et al.laboratory diagnostic aids, hospital-based epidemiologic
studies, and more importantly, the fact that the considera-
tion for Hib pneumonia may constitute a larger overall dis-
ease burden. A retrospective study based on medical records
from 13 hospitals of the causative organisms of bacterial
meningitis in Korean children over a 10 yr period (1986-
1995) showed that among children under 16 yr of age (with
the exclusion of neonates, defined as 0-28 days), H. influen-
zae was as common a cause as Streptococcus pneumoniae; respon-
sible for 34.3% of the cases. Moreover, among children under
5 yr of age, H. influenzae was the most common cause of
meningitis. The case fatality rate was 16.7% for H. influen-
zae, which was lower than that in developing countries (16-
35%) (29) and higher than those in many developed coun-
tries (30). Thus, the disease burden of H. influenzae menin-
gitis might be higher than the limited reports in Korea. 
The history of Hib conjugate vaccine goes back to the late
1980s, and few vaccines in history have induced such a dra-
matic decline in incidence over such a short period as have
the Hib conjugate vaccines (26). There are immense world-
wide data on the evidence of the safety and effectiveness of
the Hib conjugate vaccine (7, 31). Hib conjugate vaccines
not only prevent Hib disease in individuals but also facili-
tate herd immunity through reduction in carriage and trans-
mission of the organism in the community (32, 33). 
Many factors are to be considered before introducing a vac-
cine into a country. The local epidemiology of the disease,
the social cognition related to the disease and the economic
status of the country. Whereas in the past, infectious diseases
with high rates of mortality and complications were candi-
dates for vaccinations, nowadays, diseases with a low rate,
but with severe complications are considered. Even though
the local burden of the Hib disease may be lower in Korea
than in other countries, considering the effectiveness and
safety of the Hib conjugate vaccine, introduction of the vac-
cine into the routine immunization schedule should be taken
into account.
We conclude that both PRP-T and PRP-OMP conjugate
vaccines are highly immunogenic and safe in Korean infants.
Infants after a 2 dose of PRP-T and PRP-OMP have respons-
es considered acceptable for effectiveness of prevention of
disease. Further studies on the local Hib disease burden and
cost-benefit effectiveness to determine the appropriate immu-
nization schedule are needed.
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